Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Peter Barrett
AddedMar 31, 2024
UpdatedMay 31, 2026
Peter Barrett

Peter Barrett

Founder, Playground Global

CrunchbaseLinkedIn

Peter Barrett's Career

Playground Global
Playground Global

Palo Alto, CA, US

Founder
Revvity
Revvity

Waltham, MA, US

Board Member· Board
Anjuna
Anjuna

Palo Alto, CA, US

Board Member· Board
Obsidian Therapeutics
Obsidian Therapeutics

Cambridge, MA, US

Board Member· Board
Universal Hydrogen
Universal Hydrogen

Hawthorne, CA, US

Board Member· Board
Psiquantum
Psiquantum

Palo Alto, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Peter Barrett's Career

Playground Global
Playground Global
Investment FirmInvestment Firm$885M692015Palo Alto, CA, US
Founder

Recent news

GlobalFoundries advances long-term technology innovation through investment in Playground GlobalGlobalFoundries · 2026
Playground Global Announces $475 Million Fund IV to Back the Next Generation of Deep Technology CompaniesPlayground Global · 2026
Exclusive: Playground Global raises $475 million VC fundAxios · 2026

Leadership at Playground Global

Matt HershensonMatt HershensonVenture Partner
Laurie YolerLaurie YolerVenture Partner
Jon CarterJon CarterVenture Partner
Sasha OstojicSasha OstojicVenture Partner
Pat GelsingerPat GelsingerGeneral Partner
Jory BellJory BellGeneral Partner
Revvity
Revvity
Public16.7k2023Waltham, MA, US
Board Member· Board

Leadership at Revvity

Alexis MichasAlexis MichasBoard Member
Samuel R. ChapinSamuel R. ChapinBoard Member
Prahlad R SinghPrahlad R SinghCEO

Similar to Revvity

RevvityRevvityWaltham, MA, USLife Science Researchest. 1937RevvityWaltham, MA, US · est. 1937

PerkinElmer: A global leader in diagnostics, life science research, and industrial testing, operating in 190 countries.

Public16.7k
Anjuna
Anjuna
Series B$42M572018Palo Alto, CA, US
Board Member· Board

Recent news

What founders can learn from Anjuna’s layoffs and recoveryTechCrunch · 2026
TechCrunch+ roundup: Vertical AI, crypto losses decline, machine learning investor surveyTechCrunch · 2023

Leadership at Anjuna

Ayal YogevAyal YogevFounder & CEO
Yan MichalevskyYan MichalevskyCo-Founder
Lonne JaffeLonne JaffeBoard Member

Similar to Anjuna

EclypsiumEclypsiumPortland, OR, USSecurity Softwareest. 2017EclypsiumPortland, OR, US · est. 2017

Eclypsium: A cloud-based platform fortifying firmware and hardware across devices.

Series B · $49M110
EnveilEnveilFulton, MD, USData Security, Privacyest. 2016EnveilFulton, MD, US · est. 2016

Enveil, Inc.: A data security firm enabling encrypted operations in the cloud for diverse sectors.

Series B · $40M71
FortanixFortanixMountain View, CA, USData Security, Key Managementest. 2016FortanixMountain View, CA, US · est. 2016

Fortanix, Inc. provides cloud-based, self-defending data security and key management solutions in California.

Series C · $135.3M297
ShieldIOShieldIOReno, NV, USData Security, Encryptionest. 2018ShieldIOReno, NV, US · est. 2018

ShieldIO: A data security platform providing robust encryption and protection solutions against data breaches.

Angel · $800k30
Obsidian Therapeutics
Obsidian Therapeutics
Series B$164.5M902015Cambridge, MA, US
Board Member· Board

Leadership at Obsidian Therapeutics

Tariq KassumTariq KassumCo-Founder
Steve ShamahSteve ShamahCo-Founder
Heidi HagenHeidi HagenBoard Member
Madan JagasiaMadan JagasiaCEO
Anders GötzscheAnders GötzscheBoard Member
Michael GladstoneMichael GladstoneBoard Member

Similar to Obsidian Therapeutics

Odyssey TherapeuticsOdyssey TherapeuticsCambridge, MA, USPrecision Medicine, Therapeuticsest. 2021Odyssey TherapeuticsCambridge, MA, US · est. 2021

Odyssey Therapeutics: Innovating rapid, groundbreaking solutions in precision oncology and inflammation medicine.

Series C · $487M175
OmniCyteOmniCyteBranford, CT, USCancer Treatmentest. 2012OmniCyteBranford, CT, US · est. 2012

Omnicyte: Innovating targeted cancer therapies via proprietary Immuno-Oncology Platform Technology.

Angel · $366k7
Universal Hydrogen
Universal Hydrogen

Hawthorne, CA, US

Board Member· Board
Psiquantum
Psiquantum

Palo Alto, CA, US

Board Member· Board

Peter Barrett's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuHaeil YiHaeil YiCo-Founder · DunamuHyoung-nyon KimHyoung-nyon KimCo-Founder · Dunamu

People Similar to Peter Barrett

Anthony ShuberAnthony ShuberFounder · Exact SciencesMatt PetersMatt PetersCo-Founder · CortexMike GiardelloMike GiardelloCo-Founder · Mount Wilson VenturesFrank BarlettaFrank BarlettaCo-Founder · UptopBob GoodmanBob GoodmanBoard Member · ResolveXChris RyanChris RyanCo-Founder · NatureWorks